Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan

Journal of Pharmacological Sciences

Volumn 119, Issue 2, 2012, Pages 131-138

  Lei, Bai ^a   Nakano, Daisuke ^a   Fan, Yu Yan ^a   Kitada, Kento ^a   Hitomi, Hirofumi ^a   Kobori, Hiroyuki ^a   Mori, Hirohito ^a   Masaki, Tsutomu ^a   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Aliskiren; Diabetic nephropathy; Valsartan

Indexed keywords

ALISKIREN; ANGIOTENSIN II; DESMIN; GLUCOSE; MESSENGER RNA; PROTEIN P21; RENIN; VALSARTAN;

ADD ON THERAPY; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MICROALBUMINURIA; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE;

EID: 84863103139     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12031FP     Document Type: Article

References (46)

1. Habibi J, Hayden MR, Sowers JR, Pulakat L, Tilmon RD, Manrique C, et al. Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology. 2011;152:659-668.
2. Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1009-R1022.
3. Nakano D, Diah S, Kitada K, Hitomi H, Mori H, Masaki T, et al. Short-term calorie restriction in early life attenuates the development of proteinuria but not glucose intolerance in type 2 diabetic oletf rats. ISRN Endocrinology. In press.
4. Boor P, Floege J. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol. 2011;38:391-400.
5. Ihara G, Kiyomoto H, Kobori H, Nagai Y, Ohashi N, Hitomi H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens. 2010;28:2289-2298.
6. Toba H, Mitani T, Takahashi T, Imai N, Serizawa R, Wang J, et al. Inhibition of the renal renin-angiotensin system and reno-protection by pitavastatin in type 1 diabetes. Clin Exp Pharmacol Physiol. 2010;37:1064-1070.
7. Menne J, Chatzikyrkou C, Haller H. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade. J Hypertens. 2010;28:1983-1994.
8. Ruggenenti P, Fassi A, Ilieva AP, Iliev IP, Chiurchiu C, Rubis N, et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens. 2011;29:207-216.
9. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907-917.
10. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446. (Pubitemid 351793017)
11. Ina K, Kitamura H, Okeda T, Nagai K, Liu ZY, Matsuda M, et al. Vascular cell adhesion molecule-1 expression in the renal interstitium of diabetic KKAy mice. Diabetes Res Clin Pract. 1999; 44:1-8. (Pubitemid 29446183)
12. Sasaki M, Uehara S, Ohta H, Taguchi K, Kemi M, Nishikibe M, et al. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice. Life Sci. 2004;75:869-880. (Pubitemid 38737423)
13. Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, et al. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Am J Physiol Renal Physiol. 2009;297: F802-F808.
14. Rafiq K, Nakano D, Ihara G, Hitomi H, Fujisawa Y, Ohashi N, et al. Effects of mineralocorticoid receptor blockade on glucocorticoid- induced renal injury in adrenalectomized rats. J Hypertens. 2011;29:290-298.
15. Fan YY, Kohno M, Hitomi H, Kitada K, Fujisawa Y, Yatabe J, et al. Aldosterone/mineralocorticoid receptor stimulation induces cellular senescence in the kidney. Endocrinology. 2011;152: 680-688.
16. Nakano D, Lei B, Kitada K, Hitomi H, Kobori H, Mori H, et al. Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice. Am J Hypertens. 2012;25:354-358.
17. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/ salt-induced hypertensive rats. Hypertension. 2004;43:841-848. (Pubitemid 38405598)
18. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin- converting enzyme inhibition. J Am Soc Nephrol. 2002; 13:2207-2212. (Pubitemid 34925230)
19. Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, et al. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens. 2008;26: 1849-1859.
20. Verzola D, Gandolfo MT, Gaetani G, Ferraris A, Mangerini R, Ferrario F, et al. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2008;295:F1563-F1573.
21. Ogawa S, Nako K, Okamura M, Senda M, Mori T, Ito S. Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy. Hypertens Res. 2011;34:400-401.
22. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, et al. Effects of combined ace inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003;63:1094-1103. (Pubitemid 36315589)
23. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190-1198. (Pubitemid 43246436)
24. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25: 1921-1926. (Pubitemid 47356634)
25. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15: 3126-3133. (Pubitemid 39578845)
26. Azizi M, Menard J, Bissery A, Guyene TT, Bura-Riviere A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol. 2007;2:947-955.
27. Fan YY, Baba R, Nagai Y, Miyatake A, Hosomi N, Kimura S, et al. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res. 2006;29:169-178.
28. Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH, et al. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol. 2010;299:F929-F941.
29. Dong YF, Liu L, Lai ZF, Yamamoto E, Kataoka K, Nakamura T, et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens. 2010;28: 1554-1565.
30. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.
31. Kang JJ, Toma I, Sipos A, Meer EJ, Vargas SL, Peti-Peterdi J. The collecting duct is the major source of prorenin in diabetes. Hypertension. 2008;51:1597-1604.
32. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007;35:1418-1428. (Pubitemid 47121784)
33. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther. 1997;62:272-278. (Pubitemid 27417792)
34. Iqbal M, Khuroo A, Batolar LS, Tandon M, Monif T, Sharma PL. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy indian male volunteers. Clin Ther. 2010;32:588-596.
35. Prokai A, Peti-Peterdi J. Recent advances in tissue (pro)renin imaging. Front Biosci (Elite Ed). 2010;2:1227-1233.
36. Peti-Peterdi J, Sipos A. A high-powered view of the filtration barrier. J Am Soc Nephrol. 2010;21:1835-1841.
37. Amsellem S, Gburek J, Hamard G, Nielsen R, Willnow TE, Devuyst O, et al. Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am Soc Nephrol. 2010;21: 1859-1867.
38. Sangalli F, Carrara F, Gaspari F, Corna D, Zoja C, Botti L, et al. Effect of ace inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. Am J Physiol Renal Physiol. 2011;300:F1291-F1300.
39. Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and altered microvascular permeability. J Pathol. 2012;226:562-574.
40. Goldberg S, Adair-Kirk TL, Senior RM, Miner JH. Maintenance of glomerular filtration barrier integrity requires laminin alpha5. J Am Soc Nephrol. 2010;21:579-586.
41. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, et al. Combined age inhibition and acei decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int. 2006;70:507-514. (Pubitemid 44141577)
42. Gao Q, Shen W, Qin W, Zheng C, Zhang M, Zeng C, et al. Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant. 2010;25:3539-3547.
43. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, et al. Enhanced effect of combined treatment with smp-534 (antifibrotic agent) and losartan in diabetic nephropathy. Am J Nephrol. 2006;26:50-58.
44. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol. 2005;16:703-711. (Pubitemid 41725107)
45. Iwai M, Kanno H, Tomono Y, Inaba S, Senba I, Furuno M, et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens. 2010;28:1471-1481.
46. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst. In press.